Every material Form 8-K Exelixis filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Exelixis said General Counsel Jeffrey Hessekiel will step down, with his role ending November 7, 2025, and that his decision did not stem from any disagreement with the company. Brenda Hefti, currently Senior Vice President of Intellectual Property and Licensing, will take over as General Counsel on the same date, reporting to CEO Michael Morrissey. The change is a leadership transition in a legal role; the filing gives no financial figures.
Jeffrey Hessekiel, Executive Vice President and General Counsel, notified the company on November 4, 2025 of his resignation; he ceases the role November 7, 2025
Brenda Hefti, Senior Vice President, IP & Licensing, is promoted to General Counsel effective November 7, 2025
Hefti joined Exelixis in 2013 as corporate counsel and has led IP & Licensing since 2020
The filing states Hessekiel's departure was not the result of any disagreement with the company
Exelixis reported third-quarter 2025 total revenues of $597.8 million, up from $539.5 million a year earlier, and GAAP diluted earnings per share of $0.69, up from $0.40. The company raised the low end of its 2025 total revenue guidance and authorized a stock repurchase program of up to $750 million that runs through December 31, 2026.
Q3 2025 total revenues $597.8 million vs. $539.5 million in Q3 2024; net product revenues $542.9 million vs. $478.1 million
GAAP net income $193.6 million ($0.69 diluted EPS) vs. $118.0 million ($0.40) a year earlier; non-GAAP diluted EPS $0.78 vs. $0.47
2025 total revenue guidance raised to $2.30 billion-$2.35 billion from $2.25 billion-$2.35 billion; R&D expense guidance lowered to $850 million-$900 million from $925 million-$975 million
Board authorized repurchase of up to $750 million of common stock before December 31, 2026; Q3 restructuring expenses were $19.8 million
Exelixis said its board appointed Dana T. Aftab, Ph.D., currently Chief Scientific Officer, as Executive Vice President, Research and Development, effective August 29, 2025. The filing also states that Amy C. Peterson, M.D., concluded her service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer on the same date, and that she is entitled to payments under the company's Change in Control and Severance Benefit Plan. The changes affect the company's senior research and medical leadership, and the filing does not disclose the amount of Dr. Peterson's payments.
Dana T. Aftab, Ph.D., appointed Executive Vice President, Research and Development, effective August 29, 2025
Aftab was previously Executive Vice President, Discovery and Translational Research and Chief Scientific Officer
Amy C. Peterson, M.D., concluded service as EVP, Product Development and Medical Affairs and Chief Medical Officer effective August 29, 2025
Peterson is entitled to payments under the Change in Control and Severance Benefit Plan; amounts not disclosed in the filing
Exelixis reported second-quarter 2025 total revenues of $568.3 million, down from $637.2 million a year earlier, and GAAP diluted EPS of $0.65, down from $0.77. Net product revenues rose to $520.0 million from $437.6 million, but the prior-year quarter included a $150.0 million commercial milestone that lifted collaboration revenue. The company maintained its full-year 2025 financial guidance.
Total revenues were $568.3 million versus $637.2 million in Q2 2024; collaboration revenues fell to $48.2 million from $199.6 million.
Net product revenues rose to $520.0 million from $437.6 million, mainly due to higher sales volume.
GAAP diluted EPS was $0.65 versus $0.77; non-GAAP diluted EPS was $0.75 versus $0.84.
Full-year 2025 total revenue guidance of $2.25 billion to $2.35 billion was maintained.
Exelixis reported first-quarter 2025 total revenues of $555.4 million, up from $425.2 million a year earlier, and GAAP diluted earnings per share of $0.55, up from $0.12. The company raised its 2025 total revenue guidance by $100 million, to $2.25 billion to $2.35 billion, and net product revenue guidance to $2.05 billion to $2.15 billion, citing growth in CABOMETYX demand.
Q1 2025 total revenues were $555.4 million, versus $425.2 million in Q1 2024; net product revenues were $513.3 million.
GAAP diluted EPS was $0.55 and non-GAAP diluted EPS was $0.62, versus GAAP diluted EPS of $0.12 in Q1 2024.
2025 total revenue guidance is now $2.25 billion to $2.35 billion, up from $2.15 billion to $2.25 billion.
Stock repurchases totaled $494.5 million through March 31, 2025, at an average price of $34.87 per share.
Exelixis's board approved a one-time performance-based restricted stock unit program covering all employees, including named executive officers, to align staff interests with shareholders and retain employees over a five-year period. Awards vest only if the 90-day volume-weighted average stock price reaches $60 per share within five years and the employee stays employed through the fifth anniversary.
Board approved the Special Equity Award Program on March 28, 2025, covering all employees and subsidiaries.
Named executive officers received 589,719 (Morrissey), 170,009 (Senner), 132,819 (Aftab), 154,070 (Hessekiel) and 159,383 (Peterson) PSU shares.
Awards vest only if the 90-day volume-weighted average closing price equals or exceeds $60 per share within the five-year performance period; otherwise all are forfeited.
Form of award agreement for vice president level and above will be filed with the Form 10-Q for the period ending April 4, 2025.
Exelixis reported fourth-quarter 2024 total revenues of $567 million, up from $480 million a year earlier, and GAAP diluted EPS of $0.48, up from $0.27. For fiscal 2024, total revenues were $2.17 billion and GAAP net income was $521.3 million, compared with $1.83 billion and $207.8 million in 2023. The company kept its 2025 financial guidance unchanged, and that guidance does not include any impact from a possible U.S. approval of CABOMETYX for neuroendocrine tumors.
Q4 2024 net product revenues were $515.2 million, versus $429.3 million in Q4 2023.
Q4 2024 non-GAAP diluted EPS was $0.55, versus $0.33 a year earlier.
2025 total revenues guidance is $2.15 billion to $2.25 billion, unchanged from prior guidance.
The FDA's PDUFA target action date for CABOMETYX in advanced neuroendocrine tumors is April 3, 2025.
Exelixis reported preliminary, unaudited fiscal 2024 results and gave 2025 guidance, with total revenues of about $2.165 billion and net product revenues of about $1.805 billion for 2024. The audit is ongoing and the figures could change, with audited results due February 11, 2025. The 2025 net product revenue guidance of $1.95 billion to $2.05 billion sits above the 2024 preliminary figure, which points to expected growth for the cabozantinib franchise.
Preliminary fiscal 2024 total revenues of about $2.165 billion and net product revenues of about $1.805 billion
2025 guidance: total revenues of $2.15 billion to $2.25 billion; net product revenues of $1.95 billion to $2.05 billion
2025 research and development expenses guided at $925 million to $975 million; SG&A at $475 million to $525 million
Audited fiscal 2024 results scheduled for release February 11, 2025; the figures could change before then
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Exelixis filing is on SEC EDGAR ↗. 8-K briefs of other companies →